Recent work suggests a prominent role for adipose inflammation in diet induced obesity (DIO) and its metabolic and cardiovascular complications. For example, CCR2, a chemokine receptor, has been implicated in inflammatory monocyte recruitment into obese adipose and into neointima of atherosclerosis. Fractalkine (CX3CL1) and its monogamous receptor (CX3CR1) are also atherogenic and emerging data show additive roles for CX3CL1-CX3CR1 and CCR2 in atherosclerosis. In preliminary studies, we demonstrate that CX3CL1 is markedly induced in adipose inflammation, adipose CX3CL1 is increased in human and rodent obesity, fatty acids and adipocytokines induce CX3CL1 in adipocytes, monocytes adhere to human adipocytes in a CX3CR1-dependent manner, and CX3CR1 deficiency modulates adipose function and energy homeostasis in high-fat fed mice. Thus, CX3CL1-CX3CR1 appears to be one of very few chemokine pathways implicated in both obesity and atherosclerosis and therefore is the focus of this proposal. Further, unlike other chemokines e.g., CCR2, CX3CL1-CX3CR1 may be a relatively safe therapeutic target in human. We propose that CX3CL1 recruits circulating monocytes, independent of CCR2, driving adipose tissue macrophage (ATM) accumulation and survival, leading to insulin resistance and obesity on high-fat diet. The goal of this proposal, using mice models and human translation, is to determine whether fractalkine (CX3CL1-CX3CR1) modulates adipose inflammation and its metabolic consequences and if this action is independent of CCR2.
Aim 1 will characterize effects of CX3CL1 deficiency and disruption of CX3CR1 signaling on diet-induced adipose inflammation, energy and glucose homeostasis, and obesity in mice.
Aim 2 will determine how CX3CL1 interacts with CCR2 in diet-induced adipose inflammation, insulin resistance and obesity in mice.
Aim 3 will address the hypothesis that functional variation in CX3CR1 will affect adipose inflammation and insulin resistance in humans. We will also utilize adipocytes, derived from mouse embryonic fibroblast, and primary human adipocytes to study the role of CX3CL1 in adipocyte induction of monocyte recruitment, adhesion, activation and survival. These studies will define causality and mechanism while providing the human context for clinical and therapeutic development of CX3CL1-CX3CR1 in DIO and its complications.

Public Health Relevance

Adipose inflammation contributes to metabolic complications including diabetes and heart disease in obesity. We hypothesize that fractalkine, which can recruit inflammatory cells to tissues, promotes adipose inflammation and metabolic complications on high-fat diets and obesity. We will test whether deletion of fractalkine signaling in mice or genetic variation in humans blocks adipose inflammation and its metabolic complications. This work may lead to novel therapeutics that block fractalkine action and thus reduce complications of obesity including diabetes and heart disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK090505-02
Application #
8303255
Study Section
Clinical and Integrative Diabetes and Obesity Study Section (CIDO)
Program Officer
Abraham, Kristin M
Project Start
2011-07-19
Project End
2016-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
2
Fiscal Year
2012
Total Cost
$563,446
Indirect Cost
$210,785
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ballantyne, Rachel L; Zhang, Xuan; Nuñez, Sara et al. (2016) Genome-wide interrogation reveals hundreds of long intergenic noncoding RNAs that associate with cardiometabolic traits. Hum Mol Genet 25:3125-3141
Golbus, Jessica R; Stitziel, Nathan O; Zhao, Wei et al. (2016) Common and Rare Genetic Variation in CCR2, CCR5, or CX3CR1 and Risk of Atherosclerotic Coronary Heart Disease and Glucometabolic Traits. Circ Cardiovasc Genet 9:250-8
Manichaikul, Ani; Wang, Xin-Qun; Zhao, Wei et al. (2016) Genetic association of long-chain acyl-CoA synthetase 1 variants with fasting glucose, diabetes, and subclinical atherosclerosis. J Lipid Res 57:433-42
Ferguson, Jane F; Xue, Chenyi; Hu, Yu et al. (2016) Adipose tissue RNASeq reveals novel gene-nutrient interactions following n-3 PUFA supplementation and evoked inflammation in humans. J Nutr Biochem 30:126-32
Shah, Rachana; Matthews, Gregory J; Shah, Rhia Y et al. (2015) Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 66:266-73
Patel, Parth N; Shah, Rhia Y; Ferguson, Jane F et al. (2015) Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arterioscler Thromb Vasc Biol 35:525-34
Zhong, Ming; Zhang, Hanrui; Reilly, John P et al. (2015) ABO Blood Group as a Model for Platelet Glycan Modification in Arterial Thrombosis. Arterioscler Thromb Vasc Biol 35:1570-8
Qamar, Arman; Khetarpal, Sumeet A; Khera, Amit V et al. (2015) Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol 35:1880-8
Shah, Rachana; O'Neill, Sean M; Hinkle, Christine et al. (2015) Metabolic Effects of CX3CR1 Deficiency in Diet-Induced Obese Mice. PLoS One 10:e0138317
Ferguson, Jane F; Shah, Rhia Y; Shah, Rachana et al. (2015) Activation of innate immunity modulates insulin sensitivity, glucose effectiveness and pancreatic β-cell function in both African ancestry and European ancestry healthy humans. Metabolism 64:513-20

Showing the most recent 10 out of 26 publications